Biostar Pharmaceuticals, Inc. (BSPM)

[GorillaGorilla]

CPBY - difficult compare - CPBY's barriers to entry are governement contacts. They have, like most large project companies in china, problems with cash flow (from memory). CPBY is certainly undervalued, still after the rise, for it's growth potential and is a long term play on the modernising of China. My only benefit from CPBY's rise is I will get a few points in my fool.com stock game.


Uplisting - as you may know they are obliged to uplist. They could have gone to AMEX but clearly they haven't. However, I can't think this has been written into a press release. If you talk to IR about uplisting then they without prompting talk about Nasdaq. If you listen to the recording of the CC then I *think* they get asked that very question.

http://finance.yahoo.com/news/Earnings-Conference-Call-prnews-613598335.html?x=0&.v=72

rich